Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
205 pending office actions • 71 clients • 181 examiners • 68 art units • 0 of 205 (0%) have an AI response strategy ready • 165 patents granted in the last 365 days
pH IP Law manages an extensive portfolio of 6757 career applications in Biotechnology & Pharmaceuticals. The firm has a resolved allowance rate of 79.62 percent. Prosecution typically involves 3.89 office actions per allowance. There are 169 pending office actions currently.
The 79.62 percent allowance rate is a key metric for this large-scale practice. The 3.89 office actions per allowance figure reflects the complexity of the biotechnology sector. With 6757 career applications, the firm has a very deep history in this field. The 169 pending office actions represent a significant ongoing workload, indicating a very active prosecution practice.
Based on the USPTO statutory response window for each pending office action. 78 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 78 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 19 (9%) |
| §103 only | 47 (23%) |
| §102 only | 5 (2%) |
| §112 only | 16 (8%) |
| Double-patenting only | 4 (2%) |
| Double-patenting + other | 33 (16%) |
| Multi-statute (no §101) | 80 (39%) |
| No statute on record | 1 (0%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, WILLIAM A | 3 | 49.2% | +38.2% |
| NGUYEN, QUANG | 3 | 38.0% | +52.6% |
| KNIGHT, TERESA E | 2 | 65.9% | +48.5% |
| HOERNER, PAUL ELLSWORTH | 2 | 50.0% | +62.1% |
| MCLEOD, AFRICA MHAIRIE | 2 | 51.9% | +67.5% |
| NGUYEN, NGHI V | 2 | 53.6% | +50.8% |
| CORDAS, EMILY ANN | 2 | 50.8% | +57.3% |
| RAHMAN, MASUDUR | 2 | 72.7% | +31.7% |
| SALMON, KATHERINE D | 2 | 42.8% | +37.9% |
| CHONG, KIMBERLY | 2 | 72.4% | +13.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916998 | DECELLULARIZED MENISCAL CARTILAGE AND USES THEROF | MITCHELL, EDWIN COLEMAN | 111d overdue |
| 17047967 | MITOCHONDRIAL RNA IMPORT FOR TREATING MITOCHONDRIAL DISEASE | VYAS, KEYUR ANILKUMAR | 87d overdue |
| 17429182 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | FAY, ZOHREH ALEMZADEH | 73d overdue |
| 17693062 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | GOTFREDSON, GAREN | 60d overdue |
| 18873924 | ZINC IMIDAZOLE SALICYLALDOXIME-BASED ADSORPTIVE MEMBRANES FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTIONS | MCCULLOUGH, ERIC J. | 42d overdue |
| 18432898 | METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION | ADAMS, MICHELLE | 42d overdue |
| 17998194 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | OGUNBIYI, OLUWATOSIN A | 36d overdue |
| 17782314 | A BIOMARKER AND USES THEREFOR | KAPUSHOC, STEPHEN THOMAS | 32d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | SALMON, KATHERINE D | 161d overdue |
| 16933773 | NUCLEIC ACID PURIFICATION | NGUYEN, QUANG | 100d overdue |
| 16098145 | IMPROVED DRUG FORMULATIONS | CRAIGO, WILLIAM A | 98d overdue |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | SALMON, KATHERINE D | 28d overdue |
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | MCLEOD, AFRICA MHAIRIE | 8d overdue |
| 17819268 | DRY LIPOSOME FORMULATIONS AND RELATED METHODS THEREOF | HOERNER, PAUL ELLSWORTH | 4d overdue |
| 18271294 | DRIED CELL SECRETOME-BASED THERAPEUTIC AGENT FOR OSTEOARTHRITIS TREATMENT | RAHMAN, MASUDUR | 27d |
| 18789888 | BIOCHEMICAL AND BIOMECHANICAL CONDITIONING FOR ENHANCING PERSONALIZED MESENCHYMAL STEM CELL THERAPIES | KNIGHT, TERESA E | — |
| Art Unit | Apps |
|---|---|
| 1682 | 9 |
| 1632 | 8 |
| 1635 | 7 |
| 1681 | 6 |
| 1615 | 5 |
| 1658 | 5 |
| 1612 | 5 |
| 1644 | 5 |
| 1683 | 5 |
| 1631 | 5 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19461491 | Untitled | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MIDDLETON, DANAYA L | §103§112 | Non-Final OA | — | Pending | ||
| 19637493 | JELLYFISH COLLAGEN USE | Jellagen Limited | MELLER, MICHAEL V | 1655 | §103 | Non-Final OA | — | Pending | Apr 02, 2026 |
| 19363455 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | Curevac Manufacturing GmbH | BAKSHI, PANCHAM | 1623 | §103 | Non-Final OA | — | Pending | Oct 20, 2025 |
| 19118598 | MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION | VANDERBILT UNIVERSITY | ROY, BAISAKHI | 3797 | §101§103§112 | Non-Final OA | — | Pending | Apr 04, 2025 |
| 19110271 | COMPOSITION FOR ENHANCING IMMUNITY | Kolmar Bnh Co., Ltd. | SPAINE, ROBERT FRANKLIN | 1655 | §101§103§112 | Non-Final OA | — | Pending | Mar 10, 2025 |
| 19052850 | ELECTRIC-FIELD DIRECTED NERVE REGENERATION | UNIVERSITY OF SOUTHERN CALIFORNIA | LEE, BRYAN MCALLISTER | §101§103 | Non-Final OA | — | Pending | Feb 13, 2025 | |
| 19042229 | DEVICES, SYSTEMS AND METHODS FOR CLEANING OF ELONGATED INSTRUMENT SURFACE | Ascension Texas | HENDERSON, RYAN N | §102§112Other | Non-Final OA | — | Pending | Jan 31, 2025 | |
| 18980005 | SYSTEMS AND METHODS FOR CORONARY OCCLUSION TREATMENT | Research Development Foundation | LAU, MICHAEL J | §103§112 | Non-Final OA | — | Pending | Dec 13, 2024 | |
| 18873924 | ZINC IMIDAZOLE SALICYLALDOXIME-BASED ADSORPTIVE MEMBRANES FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTIONS | The Board Of Regents Of The University Of Oklahoma | MCCULLOUGH, ERIC J. | 1773 | §103§112 | Final Rejection | 42d overdue | Pending | Dec 11, 2024 |
| 18858186 | REAL-TIME BREATH ADAPTIVE NEBULIZER APPARATUS AND METHODS FOR PULMONARY THERAPEUTIC AGENT DELIVERY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ALBERS, KEVIN S | §103§112 | Non-Final OA | — | Pending | Oct 18, 2024 | |
| 18857661 | MAGNETICALLY STEERABLE CATHETER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KOLKIN, ADAM D. | 3798 | §103 | Non-Final OA | 7d | Pending | Oct 17, 2024 |
| 18856725 | DLC COATING AND PREPARATION METHOD AND DEVICE THEREFOR, COMPOSITE COATING LAYER AND COATED PRODUCT | Jiangsu Favored Nanotechnology Co., Ltd. | HORGER, KIM S. | 1717 | §103 | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18856686 | DELIVERY SYSTEM TO TARGET GRAM-NEGATIVE BACTERIA | The Wistar Institute | SHIAO, REI TSANG | §112 | Non-Final OA | — | Pending | Oct 14, 2024 | |
| 18846000 | IRREVERSIBLE ORGANIC ELECTROCHROMIC MATERIALS | UNIVERSITAET WIEN | JONES, JENNIFER ANN | §102§103§112 | Non-Final OA | — | Pending | Sep 11, 2024 | |
| 18789888 | BIOCHEMICAL AND BIOMECHANICAL CONDITIONING FOR ENHANCING PERSONALIZED MESENCHYMAL STEM CELL THERAPIES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KNIGHT, TERESA E | DP | Non-Final OA | — | Pending | Jul 31, 2024 | |
| 18833889 | NUCLEIC ACID ENCODED TRANSCRIPTION FACTOR INHIBITORS | The Schepens Eye Research Institute, Inc. | DAVIS, BRIAN J | 1614 | §112 | Final Rejection | — | Pending | Jul 27, 2024 |
| 18728949 | ISOCITRATE DEHYDROGENASE 1 INHIBITORS AND METHODS OF USE THEREOF | Case Western Reserve University | ROMERO, KRISTEN WANG | §102§103§112 | Non-Final OA | — | Pending | Jul 15, 2024 | |
| 18763115 | APPARATUS AND METHODS FOR COMPUTATIONALLY INFORMED ADHESION MEASUREMENT USING THE BLISTER TEST | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DEVITO, ALEX T | §102§103 | Non-Final OA | — | Pending | Jul 03, 2024 | |
| 18723672 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | Dongguk University Industry-Academic Cooperation Foundation | MCKOY, QUINCY ANDRE | §102DP | Non-Final OA | — | Pending | Jun 24, 2024 | |
| 18723083 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | Suzhou Kintor Pharmaceuticals, Inc. | TOWNSLEY, SARA ELIZABETH | §102§103§112DP | Non-Final OA | — | Pending | Jun 21, 2024 | |
| 18742139 | DRUG SCREENING METHOD AND MODEL FOR MONITORING PLATINUM-RESISTANT OVARIAN CANCER TUMOR GROWTH AND METASTASES | The Board Of Regents Of The University Of Oklahoma | RAGHU, GANAPATHIRAM | §102§103§112 | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18718892 | VACCINE PREPARATION | Hcemm Nonprofit Kft. | GRIZER, CASSANDRA SENN | §102§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 | |
| 18665034 | RAPID SAMPLING OF INTERSTITIAL FLUID USING A MICRONEEDLE ARRAY AND VACCUM-ASSISTED SKIN PATCH | William Marsh Rice University | BERHANU, ETSUB D | 3791 | §102§103§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18710555 | ULTRA PH-SENSITIVE MICELLES ENCAPSULATING CYTOKINES FOR TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System | CRAIGO, WILLIAM A | 1615 | §103§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18649976 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | Edward Keefer | CHERNYSHEV, OLGA N | §112DP | Non-Final OA | — | Pending | Apr 29, 2024 | |
| 18705061 | DRY POWDER COMPOSITIONS COMPRISING EUKARYOTIC CELLS AND METHOD OF THEIR MANUFACTURE AND USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | GEMBEH, SHIRLEY V | 1615 | §102§103 | Final Rejection | 70d | Pending | Apr 26, 2024 |
| 18705047 | INTRA-OPERATIVELY FITTED ANTIBIOTIC SPACER SYSTEM | The Board Of Regents Of The University Of Texas System | FLORES, ADRIAN | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | CUREVAC SE | MIANO, JOSEPH PAUL | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18703128 | TARGET ENRICHMENT AND QUANTIFICATION UTILIZING ISOTHERMALLY LINEAR-AMPLIFIED PROBES | The Children's Hospital of Philadelphia | PHAM, KHAI QUYNH TIEN | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2024 | |
| 18701465 | FACILE DIRECT AMINATION AND ALKYLAMINATION OF CARBON NANOTUBES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | RHOADES, DEREK JAMES | §102§103§112DP | Non-Final OA | — | Pending | Apr 15, 2024 | |
| 18634454 | FORMATION OF STABLE SUBMICRON PEPTIDE OR PROTEIN PARTICLES BY THIN FILM FREEZING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18700877 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Centre National De La Recherche Scientifique (Cnrs) | LADD, CAROLYN LOUISE | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | Musc Foundation For Research Development | COUNTS, GARY W | §102§103§112DP | Non-Final OA | — | Pending | Apr 11, 2024 | |
| 18627146 | HYBRID GOLD NANOPARTICLE-LIPID NANOPARTICLES AND METHODS OF USE AND PRODUCTION THEREOF | The Board Of Regents Of The University Of Oklahoma | SONG, JIANFENG | 1613 | §103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18698615 | COMPOSITE COATING, PREPARATION METHOD, AND DEVICE | Jiangsu Favored Nanotechnology Co., Ltd. | MILLER, BETHANY MACKENZIE | 1787 | §103 | Final Rejection | 27d | Pending | Apr 04, 2024 |
| 18619514 | COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES | Research Development Foundation | ARIANI, KADE | 1651 | §103§112DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18688749 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CUREVAC SE | HOERNER, PAUL ELLSWORTH | 1611 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18585375 | TRANSCRIPTION TERMINATOR BIOPARTS BASED ON 3'-UNTRANSLATED REGION (UTR) AND A METABOLIC ENGINEERING METHOD THEREOF | Korea Advanced Institute Of Science And Technology | REGLAS, GEORGIANA C | 1656 | §101§102§103 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18582620 | METHODS AND MEANS FOR ENHANCING RNA PRODUCTION | Curevac Manufacturing GmbH | DACE DENITO, ALEXANDRA GERALDINE | §103§112DP | Non-Final OA | — | Pending | Feb 20, 2024 | |
| 18436313 | SYSTEMS AND METHODS FOR STRESS DETECTION USING KINEMATIC DATA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | PHUNG, STEVEN HUYNH | §101§102§103§112 | Non-Final OA | — | Pending | Feb 08, 2024 | |
| 18432898 | METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION | Curevac Manufacturing GmbH | ADAMS, MICHELLE | 1797 | §103§112 | Final Rejection | 42d overdue | Pending | Feb 05, 2024 |
| 18293593 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | CUREVAC SE | MCLEOD, AFRICA MHAIRIE | §102 | Non-Final OA | — | Pending | Jan 30, 2024 | |
| 18292366 | IMPROVED DRUG PROCESSING METHODS TO INCREASE DRUG LOADING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SAEED, ALI S | 1616 | §103§112Other | Non-Final OA | 10d overdue | Pending | Jan 26, 2024 |
| 18291318 | MYOGENIC PROGENITOR CELLS FOR USE IN AN OPTIMIZED METHOD FOR THE PREVENTION AND TREATMENT OF ANAL INCONTINENCE | Innovacell GmbH | NGUYEN, NGHI V | 1653 | §102§103§112DP | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | CUREVAC SE | BERTOGLIO, VALARIE E | 1632 | §103§112 | Non-Final OA | 11d overdue | Pending | Jan 17, 2024 |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | Research Development Foundation | PAGUIO FRISING, MICHELLE F | 1651 | §103DP | Non-Final OA | 84d | Pending | Jan 16, 2024 |
| 18545837 | EXTRACELLULAR VESICLE-ENRICHED SECRETOME COMPOSITION DERIVED FROM INDUCED PLURIPOTENT STEM CELL DERIVED-MICROGLIA AND METHODS OF USE THEREOF | Fujifilm Holdings America Corporation | BOECKELMAN, JACOB A | 1655 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18570949 | METHODS FOR IN VIVO DELIVERY OF MICROBES TO HUMAN MICROENVIRONMENTS | BAYLOR COLLEGE OF MEDICINE | BAEK, JONGHWAN NMN | 1618 | §102§103§112DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18541241 | HUMAN ANTIBODY SPECIFICALLY BINDING TO BINDING SITE OF HEPATOCYTE RECEPTOR OF HEPATITIS B VIRUS PRES1 ANTIGEN, AND USE THEREOF | Apitbio, Inc. | BLUMEL, BENJAMIN P | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18565765 | NOVEL PRODUCTION METHOD OF FLAVOCYTOCHROME B2 | Directsens GmbH | PAK, YONG D | 1652 | §103§112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18563790 | CORRECTION OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS WITH ALL-IN-ONE ADENO-ASSOCIATED VIRUS-DELIVERED SINGLE-CUT CRISPR | The Board Of Regents Of The University Of Texas System | ALLEN, SARAH ELIZABETH | §102§103§112 | Non-Final OA | — | Pending | Nov 22, 2023 | |
| 18561900 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA | CORDAS, EMILY ANN | 1632 | §102§103DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561889 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA | WESTON, ALYSSA G | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561413 | MULTI-SPECIFIC ANTIBODY CONSTRUCTS AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ED) | DANA-FARBER CANCER INSTITUTE, INC. | CHASE, CAROL ANN | 1646 | §102§103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18559460 | METHODS AND COMPOSITIONS FOR TRANSPORT, STORAGE, AND DELIVERY OF ADENO-ASSOCIATED VIRAL VECTOR AND OTHER MOLECULES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KNIGHT, TERESA E | 1634 | §103 | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18558531 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CUREVAC SE | RAHMAN, MASUDUR | 1633 | §101§102§103 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18499054 | GLYPICAN 2 AS A CANCER MARKER AND THERAPEUTIC TARGET | The Government Of The United States Of America AS Represented By The Secretary | TAYLOR, LIA ELAN | 1641 | §112Other | Final Rejection | — | Pending | Oct 31, 2023 |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | William Marsh Rice University | SALMON, KATHERINE D | 1682 | §101§102 | Final Rejection | 28d overdue | Pending | Oct 27, 2023 |
| 18496026 | ENGINEERED LIPOSOMES FOR NEUTRALIZATION OF SARS-COV-2 AND OTHER ENVELOPED VIRUSES | VANDERBILT UNIVERSITY | WANG, RUIXUE | 1672 | §102§103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18557371 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | Helsingin Yliopisto | ANDERSON, REBECCA L | 1626 | §103§112Other | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18557033 | ADENO-ASSOCIATED VIRAL VECTORS FOR TRANSDUCTION OF COCHLEA | The Children's Hospital of Philadelphia | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18490131 | ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT | The Board Of Regents Of The University Of Texas System | CHONG, KIMBERLY | §103§112DP | Non-Final OA | — | Pending | Oct 19, 2023 | |
| 18554103 | DOPAMINERGIC PRECURSOR CELLS AND METHODS OF USE | Fujifilm Cellular Dynamics, Inc. | NGUYEN, NGHI V | 1653 | §102§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18553893 | ANTIMICROBIAL ELUTING AIRWAY DEVICES | The Children's Hospital of Philadelphia | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | — | Pending | Oct 04, 2023 |
| 18553840 | DONOR-ACCEPTOR CONJUGATED OLIGOELECTROLYTES FOR CELL LABELLING AND METHODS THEREOF | National University Of Singapore | CHONG, YONG SOO | 1623 | §102Other | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18479052 | APPARATUS AND METHODS FOR DELIVERY OF CELL COMPOSITIONS | Fujifilm Cellular Dynamics, Inc. | SUNG, GERALD LUTHER | 3741 | §102§103§112 | Non-Final OA | — | Pending | Sep 30, 2023 |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | CUREVAC SE | RYAN, DOUGLAS CHARLES | 1635 | §103 | Final Rejection | 12d | Pending | Sep 29, 2023 |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | Musc Foundation For Research Development | SZNAIDMAN, MARCOS L | 1628 | §102§103 | Non-Final OA | 10d overdue | Pending | Sep 29, 2023 |
| 18285227 | COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER | UNIVERSITY OF SOUTHERN CALIFORNIA | LEE, JIA-HAI | 1658 | §101§102§103DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18552262 | NUCLEOTIDE EDITING TO REFRAME DMD TRANSCRIPTS BY BASE EDITING AND PRIME EDITING | The Board Of Regents Of The University Of Texas System | CORDAS, EMILY ANN | 1632 | §103§112 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18471280 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | The Board Of Regents Of The University Of Texas System | CHONG, KIMBERLY | 1636 | §103§112 | Non-Final OA | — | Pending | Sep 20, 2023 |
| 18465333 | COMPOSITONS AND METHODS FOR USE OF KALIUM CHANNEL RHODOPSINS | BAYLOR COLLEGE OF MEDICINE | POPA, ILEANA | 1633 | §101§103§112 | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18549844 | GENERATION OF HUMAN PEANUT ALLERGEN-SPECIFIC IGE MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE | VANDERBILT UNIVERSITY | SANG, HONG | 1646 | §112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18549645 | DRY POWDER FORMULATIONS OF NUCLEIC ACID LIPID NANOPARTICLES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SHOMER, ISAAC | 1612 | §102§103 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SALMON, KATHERINE D | 1682 | §103 | Final Rejection | 161d overdue | Pending | Sep 07, 2023 |
| 18548413 | COLLAGENOUS EXTRACTS FOR USE AS A MEDICAMENT | Jellagen Ltd. | KATAKAM, SUDHAKAR | 1658 | §102§103§112 | Non-Final OA | 24d overdue | Pending | Aug 30, 2023 |
| 18547408 | MAGNETIC SHEAR BIOREACTOR APPARATUS AND METHODS | The Board Of Regents Of The University Of Texas System | BOWERS, NATHAN ANDREW | 1799 | §102§103 | Non-Final OA | 62d | Pending | Aug 22, 2023 |
| 18449675 | LIBRARY OF PH RESPONSIVE POLYMERS AND NANOPROBES THEREOF | The Board Of Regents Of The University Of Texas System | LAZARO, DOMINIC | 1611 | §102§103§112DP | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18546141 | LOW INTENSITY ULTRASOUND COMBINATION CANCER THERAPIES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MACFARLANE, STACEY NEE | 1675 | §103§112 | Non-Final OA | 26d | Pending | Aug 11, 2023 |
| 18264457 | LITHIATED METAL ORGANIC FRAMEWORKS WITH A BOUND SOLVENT FOR SECONDARY BATTERY APPLICATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LI, AIQUN | 1766 | §102 | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18365712 | PROCESS OF MANUFACTURE OF ANNEXIN V | Annexin Pharmaceuticals AB | IANNUZO, NATALIE NMN | 1653 | §103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18275901 | HUMANIZED GPC3 ANTIBODY AND APPLICATION THEREOF | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | JUEDES, AMY E | 1644 | §102§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18264413 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | The Board Of Regents Of The University Of Texas System | O DELL, DAVID K | 1621 | §112 | Non-Final OA | 53d | Pending | Aug 04, 2023 |
| 18274845 | HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF | Shandong Simcere Biopharmaceutical Co., Ltd. | LEE, YIE CHIA | 1642 | §112 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 18261732 | SYNTHETIC URSOLIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Reata Pharmaceuticals, Inc. | MURESAN, ANA Z | 1692 | §102 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18260891 | CROSS-REACTIVE ANTIBODIES RECOGNIZING THE CORONAVIRUS SPIKE S2 DOMAIN | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MELCHIOR, JAMES RYLAND | 1644 | §112 | Non-Final OA | — | Pending | Jul 10, 2023 |
| 18271294 | DRIED CELL SECRETOME-BASED THERAPEUTIC AGENT FOR OSTEOARTHRITIS TREATMENT | Seoul National University R&Db Foundation | RAHMAN, MASUDUR | 1633 | §103 | Final Rejection | 27d | Pending | Jul 07, 2023 |
| 18271131 | SPRAY-TYPE HYDROGEL | Seoul National University R&Db Foundation | GULLEDGE, BRIAN M | 1699 | §101§103§112 | Final Rejection | 3d overdue | Pending | Jul 06, 2023 |
| 18270915 | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL | Dongguk University Industry-Academic Cooperation Foundation | GIBBS, TERRA C | 1635 | §112 | Final Rejection | 20d | Pending | Jul 05, 2023 |
| 18270818 | NOVEL SKIN-PERMEABLE PEPTIDE, COMPOSITION INCLUDING THE SAME FOR SKIN AND MUCOUS MEMBRANE, AND USE THEREOF | Cellicon Lab Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Non-Final OA | — | Pending | Jul 03, 2023 |
| 18270476 | ORAL SOLID FORMULATION FOR COLON CLEANSING | Taejoon Pharmaceutical Co., Ltd. | ATKINSON, JOSHUA ALEXANDER | 1612 | §102§103DP | Non-Final OA | 8d overdue | Pending | Jun 29, 2023 |
| 18270070 | NOVEL YEAST STRAINS | Bisy GmbH | STEPHENS, AMELIA CAROLE | 1600 | §102§103§112 | Final Rejection | — | Pending | Jun 28, 2023 |
| 18270028 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Kunheng Pharma-Tech Co., Ltd. | HEITMEIER, KENDALL NICOLE | 1621 | §102§103Other | Final Rejection | 26d | Pending | Jun 28, 2023 |
| 18256897 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | COHEN, MICHAEL P | 1612 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | Research Development Foundation | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 28d overdue | Pending | Jun 09, 2023 |
| 18265780 | EXHAUST GAS FILTERING APPARATUS AND COATING EQUIPMENT | Jiangsu Favored Nanotechnology Co., Ltd. | PENCE, JETHRO M | 1717 | §102§103 | Final Rejection | 8d overdue | Pending | Jun 07, 2023 |
| 18254595 | DEVICE FOR PREPARING A DNA PRODUCT BY MEANS OF CAPILLARY POLYMERASE CHAIN REACTION | Tesla Automation GmbH | CROW, ROBERT THOMAS | 1683 | §102§103§112 | Non-Final OA | — | Pending | May 25, 2023 |
| 18038181 | DIRECT LYSIS APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS | Nuclein, LLC | NGUYEN, HENRY H | 1758 | §102§103 | Final Rejection | 82d | Pending | May 22, 2023 |
| 18253687 | USE OF MATURE MITOCHONDRIAL TRANSCRIPTION FACTOR A (TFAM) FOR DIAGNOSING ORGAN DYSFUNCTIONS | Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112 | Final Rejection | 29d | Pending | May 19, 2023 |
| 18320598 | RNA SEQUENCE ADAPTATION | CUREVAC SE | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Final Rejection | 62d | Pending | May 19, 2023 |
| 18253755 | USE OF MICROVIRIN IN THE IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS MANNOSE-CAPPED LIPOARABINOMANNAN | UNIVERSITY OF CAPE TOWN | DEVI, SARVAMANGALA | 1645 | §103§112 | Non-Final OA | 14d | Pending | May 19, 2023 |
| 18320187 | ARTIFICIAL NUCLEIC ACID MOLECULES | CUREVAC SE | GRAY, JESSICA | 1682 | §102§103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18037598 | SIRNA FOR TREATING HEPATIC FIBROSIS AND DELIVERY PREPARATION THEREOF | Youjia (Hangzhou) Biomedical Technology Co., Ltd. | SHEN, WU CHENG WINSTON | 1682 | §103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18037402 | COMPOSITIONS | UNIVERSITY OF SOUTHAMPTON | KATAKAM, SUDHAKAR | 1658 | §103DP | Final Rejection | — | Pending | May 17, 2023 |
| 18037282 | APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS | Nuclein, LLC | KRCHA, MATTHEW D | 1796 | §103§112 | Final Rejection | — | Pending | May 16, 2023 |
| 18252185 | METHOD FOR PREDICTING RESPONSIVENESS TO PLK1 INHIBITION | National University Of Singapore | BAUSCH, SARAE L | 1699 | §101§102 | Non-Final OA | 28d | Pending | May 08, 2023 |
| 18250532 | DIRECTIONAL AND SCALABLE ELECTRODE ARRAY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | PORTER, JR, GARY A | 3796 | §102§103 | Final Rejection | 16d overdue | Pending | Apr 25, 2023 |
| 18033464 | ANTIBODIES FOR USE IN THE DETECTION AND TREATMENT OF HEART DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MERTZ, PREMA MARIA | 1674 | §112 | Final Rejection | — | Pending | Apr 24, 2023 |
| 18250107 | BRAIN PENETRATING PEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BORGEEST, CHRISTINA M | 1675 | §102§103§112 | Final Rejection | — | Pending | Apr 21, 2023 |
| 18249647 | ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES | Avecho Biotechnology Limited | KUCHARCZK, JED A | 1623 | §103DP | Final Rejection | 2d overdue | Pending | Apr 19, 2023 |
| 18028650 | INJECTABLE CALCIUM PHOSPHATE-BASED BONE GRAFT COMPOSITION HAVING HIGH ELASTICITY AND PREPARATION METHOD THEREOF | Cg Bio Co., Ltd. | ZHANG SPIERING, DONGXIU | 1616 | §103 | Non-Final OA | — | Pending | Mar 27, 2023 |
| 18026696 | THERAPEUTIC AGENTS AND USES THEREOF | The Board Of Regents Of The University Of Texas System | HOWARD, ZACHARY C | 1674 | §102§112Other | Non-Final OA | — | Pending | Mar 16, 2023 |
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | CUREVAC SE | SHIN, DANA H | 1635 | DP | Final Rejection | 58d overdue | Pending | Mar 13, 2023 |
| 18120191 | PROGRAMMED CELLS FOR TARGETED ARTICULAR CARTILAGE AND BONE REGENERATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | BUTTICE, AUDREY L | 1644 | §102§103§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18044877 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | 16d overdue | Pending | Mar 10, 2023 |
| 18043976 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | Cyprumed GmbH | WISTNER, SARAH CLINKSCALES | 1616 | §103§112DP | Non-Final OA | — | Pending | Mar 03, 2023 |
| 18043577 | MANUFACTURING DEVICE FOR A PHARMACEUTICAL PRODUCT | Tesla Automation GmbH | SHI, TINGCHEN | 1796 | §103§112 | Final Rejection | 12d | Pending | Feb 28, 2023 |
| 18043317 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | CUREVAC SE | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18041811 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | RONEY, CELESTE A | 1612 | §103 | Non-Final OA | 16d | Pending | Feb 16, 2023 |
| 18041470 | TEXAPHYRIN DERIVATIVES FOR MANGANESE CHEMOTHERAPY, PHOTOACOUSTIC IMAGING, AND PHOTOTHERMAL THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JONES, DAMERON LEVEST | 1618 | §103 | Final Rejection | 21d | Pending | Feb 13, 2023 |
| 18041479 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ATKINSON, JOSHUA ALEXANDER | 1612 | DPOther | Final Rejection | — | Pending | Feb 13, 2023 |
| 18041475 | METHOD OF PRODUCING PHARMACEUTICAL COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BAUER, NICOLA MARIA | 1621 | §102§103§112 | Non-Final OA | — | Pending | Feb 13, 2023 |
| 18007468 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | CUREVAC SE | HAM, JIEUN | 1643 | §103 | Final Rejection | 93d overdue | Pending | Jan 30, 2023 |
| 18017669 | USE OF PERLECAN AND FRAGMENTS THEREOF TO REDUCE THE RISK OF DEATH IN STROKE PATIENTS | Stream Biomedical, Inc. | STEELE, AMBER D | 1658 | §102§103§112 | Final Rejection | 28d overdue | Pending | Jan 23, 2023 |
| 18004522 | ADENO-ASSOCIATED VIRUS VECTOR FOR DWARF OPEN READING FRAME | The Board Of Regents Of The University Of Texas System | MOLOYE, TITILAYO | 1632 | §103 | Final Rejection | — | Pending | Jan 06, 2023 |
| 18014746 | SUPER HYDROPHOBIC FILM LAYER, PREPARATION METHOD THEREOF,AND PRODUCT THEREOF | Jiangsu Favored Nanotechnology Co., Ltd. | EMPIE, NATHAN H | 1712 | §103§112 | Non-Final OA | 6d | Pending | Jan 06, 2023 |
| 18149934 | MECHANICAL OPENING OF LIPID BILAYERS BY MOLECULAR NANOMACHINES | Durham University | PERREIRA, MELISSA JEAN | §102§103DP | Non-Final OA | — | Pending | Jan 04, 2023 | |
| 18003412 | AMPLICON COMPREHENSIVE ENRICHMENT | William Marsh Rice University | BERTAGNA, ANGELA MARIE | 1681 | §101§103§112 | Final Rejection | 3d overdue | Pending | Dec 27, 2022 |
| 18001425 | MOLECULAR MARKERS AND METHODS FOR SAMPLE ANALYSIS VIA MASS SPECTROMETRY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | TURPIN, ZACHARY MARK | 1682 | §103§112 | Final Rejection | — | Pending | Dec 09, 2022 |
| 18062918 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS | Luminex Corporation | GRAY, JESSICA | 1682 | §112DP | Final Rejection | — | Pending | Dec 07, 2022 |
| 18008141 | IMPROVING ANTIBODY TOLERABILITY ASSOCIATED WITH INTRAVENOUS ADMINISTRATION | Bioinvent International AB | LEE, YIE CHIA | 1642 | §112 | Final Rejection | — | Pending | Dec 02, 2022 |
| 18060183 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | Research Development Foundation | NOBLE, MARCIA STEPHENS | 1632 | §112 | Final Rejection | 17d overdue | Pending | Nov 30, 2022 |
| 18060134 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF BONE DISORDERS | Research Development Foundation | FAN, LYNN Y | 1759 | §103 | Non-Final OA | 79d overdue | Pending | Nov 30, 2022 |
| 17999960 | NON-EXTENSIBLE OLIGONUCLEOTIDES IN DNA AMPLIFICATION REACTIONS | William Marsh Rice University | CASH, KAILEY ELIZABETH | 1683 | §102§103§112 | Non-Final OA | — | Pending | Nov 28, 2022 |
| 17999400 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | Servier Pharmaceuticals LLC | OLSON, ANDREA STEFFEL | 1693 | §102 | Final Rejection | 5d overdue | Pending | Nov 20, 2022 |
| 18056970 | METHODS, SYSTEMS AND KITS FOR POLYPEPTIDE PROCESSING AND ANALYSIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BOESEN, CHRISTIAN C | 1684 | §102§112 | Non-Final OA | — | Pending | Nov 18, 2022 |
| 18055822 | METHODS AND COMPOSITIONS FOR DETERMINING, AND FOR MINIMIZING, THE LIKELIHOOD OF DEVELOPMENT OF ALLERGY IN INFANTS | Murdoch Children'S Research Institute | WILDER, CYNTHIA B | 1681 | §101§102 | Non-Final OA | — | Pending | Nov 15, 2022 |
| 17998291 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | — | Pending | Nov 09, 2022 |
| 17998194 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | Research Development Foundation | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103§112Other | Final Rejection | 36d overdue | Pending | Nov 08, 2022 |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | Research Development Foundation | LI, RUIXIANG | 1674 | §112 | Non-Final OA | 77d overdue | Pending | Nov 03, 2022 |
| 17997696 | QUANTITATIVE BLOCKER DISPLACEMENT AMPLIFICATION (QBDA) SEQUENCING FOR CALIBRATION-FREE AND MULTIPLEXED VARIANT ALLELE FREQUENCY QUANTITATION | William Marsh Rice University | PRIEST, AARON A | 1681 | §103DP | Final Rejection | 43d overdue | Pending | Nov 01, 2022 |
| 17997453 | ALBUMIN DRUG CONJUGATES AND USE THEREOF FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LEE, JAE W | 1656 | §103 | Final Rejection | 9d overdue | Pending | Oct 28, 2022 |
| 18050687 | USE OF FATE MODULATORS TO IMPROVE NERVE REGENERATION | The Board Of Regents Of The University Of Texas System | MCCORMICK, CATHERINE LYNN | 1638 | §103§112 | Final Rejection | — | Pending | Oct 28, 2022 |
| 17996618 | LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 14d | Pending | Oct 19, 2022 |
| 17916998 | DECELLULARIZED MENISCAL CARTILAGE AND USES THEROF | The Children's Hospital of Philadelphia | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Final Rejection | 111d overdue | Pending | Oct 04, 2022 |
| 17932026 | METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE | Curevac Manufacturing GmbH | NGUYEN, QUANG | 1631 | §103 | Final Rejection | — | Pending | Sep 14, 2022 |
| 17931440 | COMPOSITIONS OF INDUCED PLURIPOTENT STEM CELL-DERIVED CELLS AND METHODS OF USE THEREOF | Fujifilm Cellular Dynamics, Inc. | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17930505 | DEEP NEURAL NETWORKS FOR ESTIMATING POLYGENIC RISK SCORES | The Board Of Regents Of The University Of Oklahoma | WHALEY, PABLO S | 3619 | §101§102§112 | Non-Final OA | — | Pending | Sep 08, 2022 |
| 17641048 | METHOD FOR SEQUENCING RNA OLIGONUCLEOTIDES | Cemm - Forschungszentrum Für Molekulare Medizin GmbH | CASH, KAILEY ELIZABETH | 1683 | §103§112 | Final Rejection | — | Pending | Sep 08, 2022 |
| 17905088 | DIBORIDE MICROPATTERNED SURFACES FOR CELL CULTURE | UNIVERSITY OF HOUSTON SYSTEM | TICHY, JENNIFER M.H. | 1653 | §103§112 | Final Rejection | — | Pending | Aug 26, 2022 |
| 17905143 | TREATMENT OF CARM1-OVEREXPRESSING AND/OR ARID1A MUTANT CANCERS WITH IRE-1/XBP-1 INHIBITORS | The Wistar Institute | SIMMONS, CHRIS E | 1622 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2022 |
| 17822332 | TARGETED MEASURE OF TRANSCRIPTIONAL ACTIVITY RELATED TO HORMONE RECEPTORS | Yale University | JOHANNSEN, DIANA B | 1682 | §103§112DP | Final Rejection | — | Pending | Aug 25, 2022 |
| 17821931 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17820277 | DIGITAL AMPLIFICATION ASSAY ANALYSIS METHOD | Luminex Corporation | KIM, YOUNG J | 1681 | Other | Final Rejection | 8d overdue | Pending | Aug 17, 2022 |
| 17820559 | METHOD FOR IN VITRO TRANSCRIPTION USING AN IMMOBILIZED RESTRICTION ENZYME | Curevac AG | POHNERT, STEVEN C | 1683 | §103§112 | Final Rejection | — | Pending | Aug 17, 2022 |
| 17819268 | DRY LIPOSOME FORMULATIONS AND RELATED METHODS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | HOERNER, PAUL ELLSWORTH | 1611 | §103Other | Non-Final OA | 4d overdue | Pending | Aug 11, 2022 |
| 17929013 | METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | QIAN, CELINE X | 1637 | §103 | Final Rejection | 51d overdue | Pending | Aug 10, 2022 |
| 17759817 | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Final Rejection | — | Pending | Jul 29, 2022 |
| 17794920 | COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES | UNIVERSITY OF SOUTHERN CALIFORNIA | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | 72d | Pending | Jul 22, 2022 |
| 17814198 | T CELLS EXPRESSING MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LIU, SUE XU | 1616 | §102§103DP | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17808180 | METHODS AND COMPOSITIONS FOR DISCRETE MELT ANALYSIS | Luminex Corporation | SISSON, BRADLEY L | 1682 | §103§112Other | Final Rejection | 56d | Pending | Jun 22, 2022 |
| 17782314 | A BIOMARKER AND USES THEREFOR | Perron Institute For Neurological And Translational Science Limited | KAPUSHOC, STEPHEN THOMAS | 1683 | §101§112 | Non-Final OA | 32d overdue | Pending | Jun 03, 2022 |
| 17782147 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JONES, DAMERON LEVEST | 1618 | §103§112 | Non-Final OA | 39d | Pending | Jun 02, 2022 |
| 17746569 | ANTI-CD300C MONOCLONAL ANTIBODY AND BIOMARKER THEREOF FOR PREVENTING OR TREATING CANCER | Centricsbio, Inc. | BERHANE, SELAM | 1675 | §112 | Non-Final OA | — | Pending | May 17, 2022 |
| 17774838 | METHODS FOR THE TREATMENT OF DYSMYELINATING/DEMYELINATING DISEASES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | NEAGU, IRINA | 1629 | §103 | Final Rejection | — | Pending | May 05, 2022 |
| 17773682 | TARGETING NONSENSE-MEDIATED DECAY TO ACTIVATE P53 PATHWAY FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ZARA, JANE J | 1637 | §102§103§112 | Non-Final OA | — | Pending | May 02, 2022 |
| 17770601 | BIOLOGICAL SAMPLE COLLECTION PAD | ZYMO RESEARCH CORPORATION | MCCORMACK, ERIN KATHLEEN | 3791 | §103§112 | Non-Final OA | — | Pending | Apr 20, 2022 |
| 17693062 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | Tff Pharmaceuticals, Inc. | GOTFREDSON, GAREN | 1619 | §103§112 | Non-Final OA | 60d overdue | Pending | Mar 11, 2022 |
| 17589879 | METHOD FOR PRODUCING RNA | Curevac Real Estate GmbH | YU, TIAN NMN | 1681 | §103 | Non-Final OA | — | Pending | Jan 31, 2022 |
| 17586258 | MUTANTS AND DRUG CONJUGATES OF R-SPONDINS AND USE THEREOF | The Board Of Regents Of The University Of Texas System | REYNOLDS, FRED H | 1658 | §112 | Final Rejection | — | Pending | Jan 27, 2022 |
| 17627385 | ANTIBODY COMBINATIONS FOR TREATMENT OF CANCER IN SPECIFIC PATIENTS | UNIVERSITY OF SOUTHAMPTON | GEORGE, DENNIS CHERIAN | 1644 | §103§112DP | Final Rejection | — | Pending | Jan 14, 2022 |
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | Curevac AG | LEITH, NANCY J | 1636 | §101§103§112Other | Non-Final OA | 30d | Pending | Jan 14, 2022 |
| 17576597 | DENDRITIC CELL IMMUNOTHERAPY | BAYLOR COLLEGE OF MEDICINE | JUEDES, AMY E | 1644 | §103§112DP | Non-Final OA | 132d overdue | Pending | Jan 14, 2022 |
| 17554861 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION | LEONARD, ARTHUR S | 1631 | §103 | Final Rejection | — | Pending | Dec 17, 2021 |
| 17620605 | METHODS FOR DUPLEX SEQUENCING OF CELL-FREE DNA AND APPLICATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | PARISI, JESSICA DANIELLE | 1684 | §103 | Final Rejection | — | Pending | Dec 17, 2021 |
| 17620047 | ROTAVIRUS MRNA VACCINE | Curevac AG | GRABER, JAMES J | 1631 | §103DP | Final Rejection | 8d overdue | Pending | Dec 16, 2021 |
| 17619096 | METHODS FOR THE PRODUCTION OF MULTIPLE LINEAGES FROM INDUCED PLURIPOTENT STEM CELLS USING CHARGED SURFACES | Fujifilm Holdings America Corporation | BEHARRY, ZANNA MARIA | 1632 | §103§112 | Final Rejection | 8d overdue | Pending | Dec 14, 2021 |
| 17548467 | SYSTEMS AND METHODS FOR LASER-INDUCED CALCIUM FRACTURES | Research Development Foundation | ANJARIA, SHREYA PARAG | 3796 | §103 | Non-Final OA | 134d overdue | Pending | Dec 10, 2021 |
| 17613292 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | AGGARWAL, SAHIL CHANDER | 1623 | §103§112DP | Non-Final OA | — | Pending | Nov 22, 2021 |
| 17611315 | METHODS AND APPARATUS FOR HIGH-SPEED AND HIGH-ASPECT RATIO LASER SUBTRACTIVE MATERIAL PROCESSING | Research Development Foundation | FEDORKY, MEGAN TAYLOR | 3796 | §103§112 | Non-Final OA | — | Pending | Nov 15, 2021 |
| 17607837 | MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS | The Trustees of the University of Pennsylvania | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Final Rejection | 6d | Pending | Oct 29, 2021 |
| 17604560 | COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Final Rejection | 12d | Pending | Oct 18, 2021 |
| 17600600 | COMBINATIONS OF TRANSCRIPTION INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112 | Non-Final OA | 19d overdue | Pending | Sep 30, 2021 |
| 17598780 | NUCLEAR-DERIVED EXOSOMES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SKOKO III, JOHN JOSEPH | 1643 | §101§103§112 | Final Rejection | 27d | Pending | Sep 27, 2021 |
| 17441869 | SURFACE-MODIFIED DOPED TITANIUM DIOXIDE NANOPARTICLES AND USES | The Board Of Regents Of The University Of Oklahoma | PROSSER, ALISSA J | 1619 | §103§112Other | Final Rejection | — | Pending | Sep 22, 2021 |
| 17429182 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | Curevac AG | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Final Rejection | 73d overdue | Pending | Aug 06, 2021 |
| 17378954 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | Curevac AG | WILSON, MICHAEL C | 1638 | §103 | Non-Final OA | 81d overdue | Pending | Jul 19, 2021 |
| 17416227 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DENT, ALANA HARRIS | 1643 | §102§103 | Final Rejection | — | Pending | Jun 18, 2021 |
| 17289877 | T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE | The Children's Hospital of Philadelphia | REDDIG, PETER J | 1646 | §103 | Non-Final OA | 30d overdue | Pending | Apr 29, 2021 |
| 17235771 | BIOLOGICALLY ACTIVE DRY POWDER COMPOSITIONS AND METHOD OF THEIR MANUFACTURE AND USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | NGUYEN, JOHN P | 1619 | §103 | Final Rejection | 17d overdue | Pending | Apr 20, 2021 |
| 17199120 | TARGETS FOR RNA THERAPEUTICS | CUREVAC SE | MCKILLOP, JOHN CHARLES | 1637 | §103 | Non-Final OA | — | Pending | Mar 11, 2021 |
| 17193511 | TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | GODDARD, LAURA B | 1642 | DP | Final Rejection | — | Pending | Mar 05, 2021 |
| 17272005 | SCALABLE TAGGING OF ENDOGENOUS GENES BY HOMOLOGY-INDEPENDENT INTRON TARGETING | The Children's Hospital of Philadelphia | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | 16d | Pending | Feb 26, 2021 |
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | The Children's Hospital of Philadelphia | MCLEOD, AFRICA MHAIRIE | 1635 | §103DP | Non-Final OA | 8d overdue | Pending | Feb 02, 2021 |
| 17146912 | METHOD FOR REDUCING THE OCCURRENCE OF THROMBOSIS OR THROMBOEMBOLISM | Grifols Shared Services North America, Inc. | BEANE, RANDALL L | 1654 | §102§103§112 | Final Rejection | 28d | Pending | Jan 12, 2021 |
| 17054312 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | William Marsh Rice University | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | 12d | Pending | Nov 10, 2020 |
| 17047967 | MITOCHONDRIAL RNA IMPORT FOR TREATING MITOCHONDRIAL DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | VYAS, KEYUR ANILKUMAR | 1637 | §101§103 | Final Rejection | 87d overdue | Pending | Oct 15, 2020 |
| 17045236 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | CUREVAC SE | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 72d overdue | Pending | Oct 05, 2020 |
| 16975058 | FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES | Mucpharm Pty Ltd. | FERNANDEZ, SUSAN EMILY | 1651 | §112 | Non-Final OA | — | Pending | Aug 21, 2020 |
| 16933773 | NUCLEIC ACID PURIFICATION | ZYMO RESEARCH CORPORATION | NGUYEN, QUANG | 1631 | §103 | Final Rejection | 100d overdue | Pending | Jul 20, 2020 |
| 16860004 | MULTIVASCULAR NETWORKS AND FUNCTIONAL INTRAVASCULAR TOPOLOGIES WITHIN BIOCOMPATIBLE HYDROGELS | William Marsh Rice University | PELLEGRINO, BRIAN E | 3799 | §103§112 | Final Rejection | — | Pending | Apr 27, 2020 |
| 16757297 | METHODS AND COMPOSITIONS FOR THE PURIFICATION OF UNBIASED RNA | ZYMO RESEARCH CORPORATION | GREENE, CAROLYN LEE | 1681 | §103 | Non-Final OA | 9d | Pending | Apr 17, 2020 |
| 16782772 | METHODS FOR DIFFERENTIATING PLURIPOTENT CELLS | Fujifilm Cellular Dynamics, Inc. | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Feb 05, 2020 |
| 16098145 | IMPROVED DRUG FORMULATIONS | AustinPx, LLC | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | 98d overdue | Pending | Nov 01, 2018 |
| 15750745 | METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE | Curevac Manufacturing GmbH | NGUYEN, QUANG | 1631 | §103 | Final Rejection | — | Pending | Feb 06, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial